Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

65.94USD
28 Apr 2017
Change (% chg)

$-0.13 (-0.20%)
Prev Close
$66.07
Open
$66.00
Day's High
$66.26
Day's Low
$65.45
Volume
1,758,226
Avg. Vol
2,063,274
52-wk High
$68.12
52-wk Low
$55.10

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.54
Market Cap(Mil.): $103,646.20
Shares Outstanding(Mil.): 1,593.58
Dividend: 0.64
Yield (%): 3.94

Financials

  ABBV.N Industry Sector
P/E (TTM): 17.82 29.41 30.38
EPS (TTM): 3.65 -- --
ROI: 12.09 13.85 13.36
ROE: 138.75 14.79 14.50

AbbVie profit beats on Humira demand; cheers Trump tax plan

AbbVie Inc reported a bigger-than-expected quarterly profit, lifted by demand for its flagship drug, Humira, and called President Donald Trump's tax plan "encouraging".

27 Apr 2017

BRIEF-Abbvie Q1 adjusted earnings per share $1.28

* Reaffirms fy 2017 gaap earnings per share view $4.55 to $4.65

27 Apr 2017

Drugmaker AbbVie's profit rises 26.4 pct

April 27 AbbVie Inc reported a 26.4 percent jump in quarterly profit on Thursday, helped by higher demand for its top-selling treatment, Humira.

27 Apr 2017

BRIEF-Aquinnah receives $10 mln investment from Pfizer, Abbvie

* Aquinnah Pharmaceuticals receives $10 million investment from Pfizer and Abbvie to research breakthrough approach to neurodegenerative disease

25 Apr 2017

BRIEF-Enanta announces eight weeks of treatment with Abbvie's investigational drug achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients

* Enanta announces eight weeks of treatment with Abbvie's investigational, pan-genotypic, ribavirin-free HCV regimen of glecaprevir/pibrentasvir (g/p) achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients

21 Apr 2017

AbbVie cancer drug fails two late-stage trials

AbbVie Inc said on Wednesday that its experimental cancer drug, veliparib, failed to meet the main goals of two late-stage studies.

20 Apr 2017

UPDATE 1-AbbVie cancer drug fails two late-stage trials

April 19 AbbVie Inc said on Wednesday that its experimental cancer drug, veliparib, failed to meet the main goals of two late-stage studies.

20 Apr 2017

AbbVie cancer drug fails two late-stage trials

April 19 AbbVie Inc said on Wednesday that its cancer drug, veliparib, failed to meet the main goals of two late-stage studies.

20 Apr 2017

BRIEF-Argen X receives first preclinical milestone payment in Abbvie collaboration

* Receives first preclinical milestone payment in abbvie collaboration

13 Apr 2017

BRIEF-U.S. FDA approves addition of moderate to severe fingernail psoriasis data to Abbvie's humira

* U.S. FDA approves addition of moderate to severe fingernail psoriasis data to Abbvie's Humira (adalimumab) prescribing information

30 Mar 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $123.47 -0.27
Pfizer Inc. (PFE.N) $33.92 +0.06
Novartis AG (NOVN.S) CHF76.55 -0.35
Merck & Co., Inc. (MRK.N) $62.33 -0.25
Roche Holding Ltd. (ROG.S) CHF260.30 0.00
Roche Holding Ltd. (RO.S) CHF260.50 -1.00
Abbott Laboratories (ABT.N) $43.64 -0.01
Eli Lilly and Co (LLY.N) $82.06 +0.73
Sanofi SA (SASY.PA) €86.61 +0.64

Earnings vs. Estimates